
Opinion|Videos|May 28, 2025
Current Challenges in the Management of Bronchiectasis
Panelists discuss how the heterogeneity of bronchiectasis requires precise phenotyping and a treatable traits approach to address varying symptom profiles, from cough-predominant to shortness of breath–predominant presentations.
Advertisement
Episodes in this series

Clinical Brief: Challenges in Managing Heterogeneous Bronchiectasis Presentations
Main Discussion Topics
- Bronchiectasis presents heterogeneously in symptoms, etiology, and severity.
- Treatment approaches should be tailored to specific phenotypes.
- Different symptom presentations require different management priorities.
Key Points for Physicians
- Recognize common symptom phenotypes:
- Cough predominant: focus on airway clearance techniques
- Dyspnea predominant with minimal cough: emphasize exercise, nutrition, and pulmonary rehabilitation
- Frequent exacerbator: targeted antibiotic strategies and infection prevention
- Perform thorough diagnostic workup to identify underlying etiologies.
- Treat comorbidities such as reflux, aspiration, and sinus disease.
- Apply a “treatable traits” approach focusing on specific characteristics rather than using a one-size-fits-all strategy.
Notable Insights
The heterogeneity of bronchiectasis necessitates precision medicine approaches tailored to individual patient presentations rather than standardized treatment algorithms.
Clinical Significance
Recognizing and addressing the varied presentations of bronchiectasis through phenotype-specific approaches improves management outcomes and patient quality of life.
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis
2
Complicated UTI Care Strained by Unclear Goals, Access Gaps
3
Obesity Care Ownership Shifts to Specialties That Win Coverage
4
Emerging Threats to Cell and Gene Therapy Access
5

